AT-33 A PHASE II STUDY OF CONCURRENT RADIATION THERAPY, TEMOZOLOMIDE AND THE HISTONE DEACETYLASE INHIBITOR VALPROIC ACID FOR PATIENTS WITH GLIOBLASTOMA MULTIFORME

Samankaltaisia teoksia

• A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid For Patients With Glioblastoma
  Tekijä: Krauze, Andra V., et al.
  Julkaistu: (2015)
• ACTR-57. DOES THE ADDITION OF VALPROIC ACID TO CONCURRENT RADIATION THERAPY AND TEMOZOLOMIDE IMPROVE PATIENT OUTCOME? – CORRELATIVE ANALYSIS OF RTOG 0525, SEER AND A PHASE II NCI TRIAL
  Tekijä: Krauze, Andra, et al.
  Julkaistu: (2017)
• Late toxicity in long-term survivors from a phase 2 study of concurrent radiation therapy, temozolomide and valproic acid for newly diagnosed glioblastoma
  Tekijä: Krauze, Andra V, et al.
  Julkaistu: (2018)
• Postradiation Sensitization of the Histone Deacetylase Inhibitor Valproic Acid
  Tekijä: Chinnaiyan, Prakash, et al.
  Julkaistu: (2008)
• Aplastic anemia with concurrent temozolomide treatment in a patient with glioblastoma multiforme
  Tekijä: Oh, J., et al.
  Julkaistu: (2010)